Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection: A prospective study

Kohei Kawase, Kenji Kondo, Takeo Saito, Ayu Shimasaki, Atsushi Takahashi, Yoichiro Kamatani, Naoto Kawabe, Senju Hashimoto, Masashi Ikeda, Michiaki Kubo, Kentaro Yoshioka, Nakao Iwata

Research output: Contribution to journalArticle

Abstract

Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.

Original languageEnglish
Pages (from-to)489-497
Number of pages9
JournalPsychiatry and Clinical Neurosciences
Volume70
Issue number11
DOIs
Publication statusPublished - 01-11-2016

Fingerprint

Virus Diseases
Hepacivirus
Interferons
Prospective Studies
Equipment and Supplies
Therapeutics
Odds Ratio

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Kawase, Kohei ; Kondo, Kenji ; Saito, Takeo ; Shimasaki, Ayu ; Takahashi, Atsushi ; Kamatani, Yoichiro ; Kawabe, Naoto ; Hashimoto, Senju ; Ikeda, Masashi ; Kubo, Michiaki ; Yoshioka, Kentaro ; Iwata, Nakao. / Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection : A prospective study. In: Psychiatry and Clinical Neurosciences. 2016 ; Vol. 70, No. 11. pp. 489-497.
@article{cefc286cd63e48c7825576d782e49729,
title = "Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection: A prospective study",
abstract = "Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3{\%}) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.",
author = "Kohei Kawase and Kenji Kondo and Takeo Saito and Ayu Shimasaki and Atsushi Takahashi and Yoichiro Kamatani and Naoto Kawabe and Senju Hashimoto and Masashi Ikeda and Michiaki Kubo and Kentaro Yoshioka and Nakao Iwata",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/pcn.12424",
language = "English",
volume = "70",
pages = "489--497",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "11",

}

Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection : A prospective study. / Kawase, Kohei; Kondo, Kenji; Saito, Takeo; Shimasaki, Ayu; Takahashi, Atsushi; Kamatani, Yoichiro; Kawabe, Naoto; Hashimoto, Senju; Ikeda, Masashi; Kubo, Michiaki; Yoshioka, Kentaro; Iwata, Nakao.

In: Psychiatry and Clinical Neurosciences, Vol. 70, No. 11, 01.11.2016, p. 489-497.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk factors and clinical characteristics of the depressive state induced by pegylated interferon therapy in patients with hepatitis C virus infection

T2 - A prospective study

AU - Kawase, Kohei

AU - Kondo, Kenji

AU - Saito, Takeo

AU - Shimasaki, Ayu

AU - Takahashi, Atsushi

AU - Kamatani, Yoichiro

AU - Kawabe, Naoto

AU - Hashimoto, Senju

AU - Ikeda, Masashi

AU - Kubo, Michiaki

AU - Yoshioka, Kentaro

AU - Iwata, Nakao

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.

AB - Aim: Pegylated interferon (PegIFN) therapies for hepatitis C virus (HCV) infection often induce a depressive state. This study aimed to identify the risk factors for and clinical characteristics of PegIFN-induced depressive state. Methods: Sixty-nine subjects with HCV who received PegIFN therapy were enrolled. Before beginning therapy, all subjects were evaluated using the Neuroticism–Extraversion–Openness Five-Factor Inventory and the List of Threatening Events Questionnaire. Beck Depression Inventory (BDI) scores were also evaluated at baseline, 2–4 weeks after initiating therapy, and every 4 weeks thereafter. Results: During the study, 18 subjects (24.3%) developed a depressive state (BDI ≥ 10). A bimodal peak of onset was observed during the early (2–8 weeks) and late (after 20 weeks) therapy phases. Moreover, we observed that baseline BDI scores (odds ratio [OR] = 1.40, P = 0.0104) and neuroticism (OR = 1.14, P = 0.0275) were significant risk factors for developing a depressive state. To determine the specific characteristics of this condition, we compared the BDI subscales between the ‘PegIFN-induced’ and ‘general’ depressive state reported previously. We found that the score at ‘somatic symptoms’ was higher in the ‘PegIFN-induced’ group. Conclusion: Our results indicate the following: (i) PegIFN-induced depressive state most frequently develops during the first 8 weeks of therapy; (ii) baseline BDI and neuroticism scores are risk factors for PegIFN-induced depressive state; and (iii) the core symptoms of PegIFN-induced depressive state are different from those of ‘general’ depression.

UR - http://www.scopus.com/inward/record.url?scp=84987654226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987654226&partnerID=8YFLogxK

U2 - 10.1111/pcn.12424

DO - 10.1111/pcn.12424

M3 - Article

C2 - 27471075

AN - SCOPUS:84987654226

VL - 70

SP - 489

EP - 497

JO - Psychiatry and Clinical Neurosciences

JF - Psychiatry and Clinical Neurosciences

SN - 1323-1316

IS - 11

ER -